Title : HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.

Pub. Date : 2017 Mar 21

PMID : 28423638






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. Iodine-131 mitogen-activated protein kinase kinase 7 Homo sapiens
2 Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. Iodine-131 mitogen-activated protein kinase kinase 7 Homo sapiens